论文部分内容阅读
目的:探讨成纤维细胞生长因子受体1(fibroblast growth factor receptor 1,FGFR1)及Survivin蛋白在乳腺浸润性导管癌(invasive ductal carcinoma,IDC)中的表达、意义及两者的相关性。方法:采用免疫组织化学SP法检测81例乳腺IDC组织石蜡标本中FGFR1及Survivin的表达情况。结果:FGFR1及Survivin蛋白阳性表达率分别为29.63%(24/81)和77.78%(63/81)。它们的表达均与患者年龄无关(χ2=0.919,P=0.338;χ2=1.442,P=0.233);但与细胞增殖指数(Ki-67)呈明显正相关(r=0.446,P<0.001;r=0.269,P=0.015);FGFR1的表达与雌激素受体(estrogen receptor,ER)呈正相关性(r=0.285,P=0.010),与孕激素受体(progesterone receptor,PR)、表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)呈负相关性(r=-0.371,P=0.001;r=-0.372,P=0.001),而与肿瘤大小(χ2=2.222,P=0.329)、腋淋巴结转移(χ2=0.424,P=0.515)、TNM分期(χ2=0.608,P=0.738)和病理组织学分级(χ2=4.514,P=0.105)差异无统计学意义;而Survivin表达与ER的表达(r=-0.145,P=0.195)和PR的表达(r=0.172,P=0.126)无关,与HER-2呈正相关性(r=0.275,P=0.013),并与肿瘤大小(χ2=21.500,P<0.001)、腋淋巴结转移(χ2=4.772,P=0.029)、TNM分期(χ2=10.792,P=0.005)及病理组织学分级(χ2=11.638,P=0.003)密切相关;FGFR1与Survivin表达呈显著正相关,r=0.347,P=0.006。结论:FGFR1和Survivin可能是乳腺IDC患者的不良预后因素;FGFR1及Survivin可能共同促进乳腺癌的细胞增殖、侵袭及转移,联合检测有助于更准确地判断乳腺IDC的预后。
Objective: To investigate the expression of fibroblast growth factor receptor 1 (FGFR1) and Survivin protein in invasive ductal carcinoma (IDC) and its significance. Methods: Immunohistochemical SP method was used to detect the expression of FGFR1 and Survivin in 81 cases of breast IDC tissues. Results: The positive rates of FGFR1 and Survivin were 29.63% (24/81) and 77.78% (63/81), respectively. Their expressions were not related to patient’s age (χ2 = 0.919, P = 0.338; χ2 = 1.442, P = 0.233), but positively correlated with cell proliferation index (Ki = = 0.269, P = 0.015). There was a positive correlation between the expression of FGFR1 and estrogen receptor (r = 0.285, P = 0.010) and the correlation between the expression of progesterone receptor (PR) and epidermal growth factor (R = -0.371, P = 0.001; r = -0.372, P = 0.001), but not with tumor size (χ2 = 2.222, P = (Χ2 = 0.414, P = 0.515). There was no significant difference in TNM stage (χ2 = 0.608, P = 0.738) and pathological grade (χ2 = 4.514, P = 0.105) (R = -0.145, P = 0.195) and PR (r = 0.172, P = 0.126), which was positively correlated with HER-2 (r = 0.275, P = 0.013) (χ2 = 21.500, P <0.001), axillary lymph node metastasis (χ2 = 4.772, P = 0.029), TNM stage (χ2 = 10.792, P = 0.005) and histological grade There was a significant positive correlation between FGFR1 and Survivin expression (r = 0.347, P = 0.006). CONCLUSIONS: FGFR1 and Survivin may be adverse prognostic factors in breast IDC patients. FGFR1 and Survivin may promote the proliferation, invasion and metastasis of breast cancer cells. Combined detection may be helpful to determine the prognosis of breast IDC more accurately.